Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.

Temozolomide (TMZ), as the first-line chemotherapeutic agent, relies on inducing DNA methylation of O6-guanine for treating glioma. However, the survival time of patients are hardly exceeded 14.5 months, attributing to inevitable drug resistance and systematic toxicity after long-term administration. Herein, reassembly-exosomes (R-EXO) deriving from homologous glioma cells is proposed to carry TMZ and Dihydrotanshinone (DHT) for reversing drug resistance and enhancing lesions-targeted drug delivery, defined as R-EXO-TMZ/DHT (R-EXO-T/D). It is found that R-EXO-T/D share various advantages, including preferable blood-brain barrier (BBB)-penetrating ability with nanomemter size, tumor-homing accumulation with homologous effects, as well as potentiated antitumor activity with overcoming TMZ resistance and triggering immune response. This work develops a new strategy for site-specific drug delivery, showing a promising application of drug compatibility in glioma treatment.

Mineral medicine: from traditional drugs to multifunctional delivery systems.

Mineral drugs are an important constituent of traditional Chinese medicine (TCM). Taking minerals that contain heavy metals as drugs is a very national characteristic part of TCM. However, the safety and scientific nature of mineral drugs are controversial owing to their heavy metals and strong toxicity. In 2000, the Food and Drug Administration (FDA) authorized arsenic trioxide (ATO) as first-line therapy for acute promyelocytic leukemia. This makes the development and utilization of mineral drugs become a research hotspot. The development of nanomedicine has found a great prospect of mineral drugs in nano-delivery carriers. And that will hold promise to address the numerous biological barriers facing mineral drug formulations. However, the studies on mineral drugs in the delivery system are few at present. There is also a lack of a detailed description of mineral drug delivery systems. In this review, the advanced strategies of mineral drug delivery systems in tumor therapy are summarized. In addition, the therapeutic advantages and research progress of novel mineral drug delivery systems are also discussed. Here, we hope that this will provide a useful reference for the design and application of new mineral drug delivery systems.

Color difference threshold determination for acrylic denture base resins.

This study aimed to set evaluation indicators, i.e., perceptibility and acceptability color difference thresholds, of color stability for acrylic denture base resins for a spectrophotometric assessing method, which offered an alternative to the visual method described in ISO 20795-1:2013. A total of 291 disk specimens 50±1 mm in diameter and 0.5±0.1 mm thick were prepared (ISO 20795-1:2013) and processed through radiation tests in an accelerated aging chamber (ISO 7491:2000) for increasing times of 0 to 42 hours. Color alterations were measured with a spectrophotometer and evaluated using the CIE L*a*b* colorimetric system. Color differences were calculated through the CIEDE2000 color difference formula. Thirty-two dental professionals without color vision deficiencies completed perceptibility and acceptability assessments under controlled conditions in vitro. An S-curve fitting procedure was used to analyze the 50:50% perceptibility and acceptability thresholds. Furthermore, perceptibility and acceptability against the differences of the three color attributes, lightness, chroma, and hue, were also investigated. According to the S-curve fitting procedure, the 50:50% perceptibility threshold was 1.71ΔE00 (r(2)=0.88) and the 50:50% acceptability threshold was 4.00 ΔE00 (r(2)=0.89). Within the limitations of this study, 1.71/4.00 ΔE00 could be used as perceptibility/acceptability thresholds for acrylic denture base resins.